Scarica l'app Stockscreener
33.62
2.15%
-0.74
Precedente Chiudi:
$34.36
Aprire:
$34.36
Volume 24 ore:
723.76K
Relative Volume:
0.79
Capitalizzazione di mercato:
$2.61B
Reddito:
$688.00K
Utile/perdita netta:
$-170.19M
Rapporto P/E:
-11.02
EPS:
-3.0495
Flusso di cassa netto:
$-154.68M
1 W Prestazione:
+0.51%
1M Prestazione:
+43.49%
6M Prestazione:
+89.84%
1 anno Prestazione:
+40.55%
Intervallo 1D:
$33.24
$35.17
Intervallo di 1 settimana:
$33.24
$35.31
Portata 52W:
$10.91
$35.31
Spyre Therapeutics Inc Stock (SYRE) Company Profile
Nome
Spyre Therapeutics Inc
Settore
Industria
Telefono
(617) 651-5940
Indirizzo
221 CRESCENT STREET, WALTHAM
Confronta SYRE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
33.62 | 2.67B | 688.00K | -170.19M | -154.68M | -3.0495 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-26 | Iniziato | Deutsche Bank | Buy |
| 2025-04-08 | Iniziato | Leerink Partners | Outperform |
| 2025-03-18 | Iniziato | Wolfe Research | Outperform |
| 2024-09-04 | Iniziato | Wedbush | Outperform |
| 2024-07-16 | Iniziato | Evercore ISI | Outperform |
| 2024-05-02 | Iniziato | Robert W. Baird | Outperform |
| 2024-03-01 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-12-20 | Iniziato | BTIG Research | Buy |
| 2023-12-11 | Iniziato | Guggenheim | Buy |
| 2023-12-11 | Iniziato | Jefferies | Buy |
| 2020-05-04 | Iniziato | Piper Sandler | Overweight |
| 2019-03-21 | Iniziato | JP Morgan | Overweight |
| 2018-09-04 | Downgrade | Wells Fargo | Outperform → Market Perform |
| 2018-04-24 | Iniziato | Evercore ISI | Outperform |
| 2018-03-14 | Reiterato | Needham | Buy |
Mostra tutto
Spyre Therapeutics Inc Borsa (SYRE) Ultime notizie
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
60,372,927 Common Stock of Spyre Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-DEC-2025. - marketscreener.com
Certain Series A Preferred Stock of Spyre Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-DEC-2025. - marketscreener.com
Certain Series B Preferred Stock of Spyre Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-DEC-2025. - marketscreener.com
Spyre Therapeutics stock hits 52-week high at 35.0 USD - Investing.com
Spyre Therapeutics (SYRE): Assessing Valuation After a Sharp Momentum-Driven Share Price Surge - Yahoo Finance
Spyre Therapeutics (NASDAQ:SYRE) Hits New 52-Week HighShould You Buy? - MarketBeat
A Short Squeeze Could Send This Little-Known Biotech Stock Soaring - Barchart.com
Affinity Asset Advisors LLC Raises Stock Holdings in Spyre Therapeutics, Inc. $SYRE - MarketBeat
Spyre Therapeutics Announces Grants of Inducement Awards - The Manila Times
Spyre Therapeutics (NASDAQ: SYRE) issues 20,300-share inducement stock options - Stock Titan
Spyre Therapeutics (NASDAQ:SYRE) CEO Cameron Turtle Sells 15,000 Shares - MarketBeat
Will Spyre Therapeutics Inc. (3920) stock see insider accumulationEarnings Overview Report & Fast Momentum Stock Entry Tips - Newser
Spyre Therapeutics (NASDAQ:SYRE) Trading Up 7.2%Still a Buy? - MarketBeat
Spyre Therapeutics CEO Turtle Cameron sells $435k in stock By Investing.com - Investing.com UK
Spyre Therapeutics: A New Era Unfolds? - timothysykes.com
A significant driver of top-line growth: Spyre Therapeutics Inc (SYRE) - setenews.com
Spyre Therapeutics stock reaches 52-week high at 30.56 USD By Investing.com - Investing.com Nigeria
Spyre Therapeutics stock reaches 52-week high at 30.56 USD - Investing.com
Is Spyre Therapeutics Inc. (3920) stock at risk of policy regulation2025 Valuation Update & Fast Exit and Entry Trade Guides - Newser
Why Spyre Therapeutics Inc. stock is in analyst buy zone2025 AllTime Highs & Detailed Earnings Play Strategies - Newser
Spyre Therapeutics (NASDAQ:SYRE) Sets New 12-Month High on Analyst Upgrade - MarketBeat
Spyre Therapeutics (NASDAQ:SYRE) Upgraded by Jones Trading to Buy Rating - MarketBeat
What is the fair value of Spyre Therapeutics Inc. stock nowRate Hike & Verified Momentum Stock Watchlist - Newser
Spyre Therapeutics (NASDAQ:SYRE) Upgraded by Jones Trading to “Buy” Rating - Defense World
Spyre Therapeutics (NASDAQ:SYRE) Sets New 52-Week High After Analyst Upgrade - Defense World
Can Spyre Therapeutics Inc. stock deliver consistent earnings growthMarket Performance Summary & Risk Controlled Swing Alerts - Newser
Jones Trading Upgrades Spyre Therapeutics (SYRE) - Nasdaq
SYRE Stock Upgraded by Jones Trading; New Price Target Set at $6 - GuruFocus
Spyre Therapeutics, Inc. $SYRE Shares Acquired by Franklin Resources Inc. - MarketBeat
Spyre Therapeutics, Inc. $SYRE Shares Purchased by Intech Investment Management LLC - Defense World
Spyre Therapeutics, Inc. $SYRE Shares Purchased by Geode Capital Management LLC - MarketBeat
Spyre stock rating upgraded to Buy at Jones Trading on TL1A blockade potential - Investing.com Canada
Nasdaq Composite Tracks Rising Biotech Momentum At Spyre Therapeutics - Kalkine Media
What analysts say about Spyre Therapeutics Inc 3920 stockFundamental Stock Analysis & Big Returns Low Cost - earlytimes.in
Spyre Therapeutics, Inc. $SYRE Shares Sold by Universal Beteiligungs und Servicegesellschaft mbH - MarketBeat
A Look at Spyre Therapeutics Inc (SYRE) Shares in the Recent Past Indicates Growth - Setenews
Spyre Therapeutics stock hits 52-week high at 29.1 USD By Investing.com - Investing.com South Africa
Spyre Therapeutics stock hits 52-week high at 29.1 USD - Investing.com India
Why Spyre Therapeutics Inc. (3920) stock benefits from AI revolutionWeekly Market Outlook & Weekly Stock Performance Updates - newser.com
Can Spyre Therapeutics Inc. stock deliver strong Q4 earningsMarket Movers & Fast Entry High Yield Tips - newser.com
Is Spyre Therapeutics Inc. (3920) stock worth buying before Fed actionTrend Reversal & Daily Stock Momentum Reports - newser.com
Top investors say Spyre Therapeutics Inc (SYRE) ticks everything they need - Setenews
Earnings visualization tools for Spyre Therapeutics Inc. - newser.com
Will Spyre Therapeutics Inc. (3920) stock recover faster than industryJuly 2025 Patterns & Fast Entry and Exit Trade Plans - newser.com
Using data tools to time your Spyre Therapeutics Inc. exit2025 Top Gainers & Safe Entry Momentum Tips - newser.com
Why Spyre Therapeutics Inc. stock is seen as undervaluedTrend Reversal & Reliable Entry Point Trade Alerts - newser.com
Backtesting results for Spyre Therapeutics Inc. trading strategiesQuarterly Portfolio Review & Long-Term Safe Investment Plans - newser.com
Will Spyre Therapeutics Inc. (3920) stock announce special dividend2025 Earnings Impact & Accurate Intraday Trading Signals - newser.com
Spyre Therapeutics Inc Azioni (SYRE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.08%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):